Evidence map›Paper›PMID 25893199›Full record

ArticleBioMed research international2015

Acute and chronic toxicity, cytochrome p450 enzyme inhibition, and HERG channel blockade studies with a polyherbal, ayurvedic formulation for inflammation.

Debendranath Dey, Sunetra Chaskar, Nitin Athavale, Deepa Chitre

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights.Drug metabolism and disposition: the biological fate of chemicals · 2022
    Review
  4. Detection of Methicillin-ResistantVeterinary medicine international · 2022
    Article
  5. Article
  6. Withania somnifera: From prevention to treatment of cancer.Molecular nutrition & food research · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Debendranath DeyBioved Pharmaceuticals Pvt. Ltd., BAIF Bhawan, Z Wing, Warje Malwadi, Pune 411 052, India.
Sunetra ChaskarBioved Pharmaceuticals Pvt. Ltd., BAIF Bhawan, Z Wing, Warje Malwadi, Pune 411 052, India.
Nitin AthavaleBioved Pharmaceuticals Pvt. Ltd., BAIF Bhawan, Z Wing, Warje Malwadi, Pune 411 052, India.
Deepa ChitreBioved Pharmaceuticals, Inc., 1929 O'Toole Way, San Jose, CA 95131, USA.
Biota Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ayurvedic plants are known for thousands of years to have anti-inflammatory and antiarthritic effect. We have recently shown that BV-9238, a proprietary formulation of Withania somnifera, Boswellia serrata, Zingiber officinale, and Curcuma longa, inhibits LPS-induced TNF-alpha and nitric oxide production from mouse macrophage and reduces inflammation in different animal models. To evaluate the safety parameters of BV-9238, we conducted a cytotoxicity study in RAW 264.7 cells (0.005-1 mg/mL) by MTT/formazan method, an acute single dose (2-10 g/kg bodyweight) toxicity study and a 180-day chronic study with 1 g and 2 g/kg bodyweight in Sprague Dawley rats. Some sedation, ptosis, and ataxia were observed for first 15-20 min in very high acute doses and hence not used for further chronic studies. At the end of 180 days, gross and histopathology, blood cell counts, liver and renal functions were all at normal levels. Further, a modest attempt was made to assess the effects of BV-9238 (0.5 µg/mL) on six major human cytochrome P450 enzymes and (3)H radioligand binding assay with human hERG receptors. BV-9238 did not show any significant inhibition of these enzymes at the tested dose. All these suggest that BV-9238 has potential as a safe and well tolerated anti-inflammatory formulation for future use.

Indexed as

AnimalsCell LineCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsFemaleHumansInflammationLipopolysaccharidesMacrophagesMaleMiceNitric OxidePlant PreparationsPlants, MedicinalCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemERG1 Potassium ChannelEther-A-Go-Go Potassium ChannelsKCNH2 protein, humanLipopolysaccharidesNitric OxidePlant PreparationsTumor Necrosis Factor-alpha

Identifiers

PMID25893199
PMCPMC4381553
OpenAlexW1971223394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.